Nimotop (Nimodipine)

Nimodipine is used primarily in the cerebrovascular field to mitigate vasospasm after subarachnoid hemorrhage.

• Subarachnoid hemorrhage: prevents delayed cerebral vasospasm and supports neurological recovery.
• Post‑aneurysmal bleed: reduces the risk of ischemic deficits caused by vessel narrowing.
• Neurosurgical patients at risk of vasospasm: helps maintain cerebral perfusion during the acute phase.

• Nimodipine antagonizes L‑type voltage‑gated calcium channels on vascular smooth muscle, especially within cerebral arteries. By inhibiting calcium influx, it induces selective vasodilation of cerebral vessels, counteracting the constrictive response that follows subarachnoid hemorrhage and thereby improving cerebral blood flow and oxygen delivery.

Nimodipine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient blood pressure reduction.
• Nausea or vomiting: gastrointestinal discomfort.
• Flushing: warmth and redness of skin.
• Dizziness or vertigo: sensation of light‑headedness.
• Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects

• Severe hypotension: may require medical intervention.
• Myocardial ischemia or infarction: rare cardiac events.
• Hepatic dysfunction: abnormal liver enzymes.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Seizures: uncommon neurologic events.
• Hemorrhagic complications: increased bleeding tendency.

Before initiating therapy, clinicians should assess individual risk factors and monitor patients closely.

• Blood pressure monitoring: watch for hypotensive episodes.
• Hepatic function: evaluate liver enzymes prior to and during treatment.
• Cardiac disease: use cautiously in patients with existing heart conditions.
• Infusion rate: avoid rapid administration to reduce cardiovascular stress.
• Renal impairment: adjust monitoring as drug clearance may be affected.
• Store at room temperature: keep in the original container, protect from moisture and light.

Nimodipine can alter the pharmacodynamics or pharmacokinetics of several co‑administered agents.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nimodipine plasma levels.
• Other calcium channel blockers: additive vasodilatory effect leading to severe hypotension.
• Nitrates: risk of profound blood pressure drop.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance bradycardia and hypotension.
• Antihypertensive agents: require dose adjustments.
• CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic efficacy.